Daniel Young, DO
Family Medicine · Draper, UTNPI 1114301710
Payments from drug & device makers
Across 429 payments — averaging $15.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Astellas Pharma US Inc$790
- Novo Nordisk$660
- Abbott$479
- Boehringer Ingelheim$413
- GSK$410
- plus $3K from 26 others
What the payments were for
- Speaking & faculty fees$190%
- Food & beverage$6,56797%
- Education$1552%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 63 | $1,114 |
| Astellas Pharma US Inc | 33 | $790 |
| Novo Nordisk | 66 | $660 |
| Abbott | 33 | $479 |
| Boehringer Ingelheim | 22 | $413 |
| GSK | 28 | $410 |
| Amgen | 25 | $409 |
| Pfizer | 27 | $370 |
| Lilly USA, LLC | 21 | $355 |
| E.r. Squibb & Sons, L.L.C. | 20 | $314 |
| AstraZeneca | 22 | $287 |
| Johnson & Johnson | 14 | $242 |
| Sanofi-aventis U.S. LLC | 16 | $236 |
| Antares Pharma, Inc. | 7 | $103 |
| Boston Scientific | 4 | $72 |
| BD | 3 | $68 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $60 |
| Amarin Pharma, Inc. | 3 | $58 |
| Merck | 3 | $38 |
| Exact Sciences | 2 | $36 |
| Arbor Pharmaceuticals, Inc. | 2 | $29 |
| Dexcom, Inc. | 2 | $27 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Acorda Therapeutics, Inc | 1 | $19 |
| Novartis | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $18 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Medtronic | 1 | $16 |
| Mannkind Corporation | 1 | $16 |
| MDD US Operations, LLC | 1 | $15 |
| Lifescan, Inc. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
How this compares
$6,740 in reported general payments places this provider in the 85th percentile of 928 family medicine providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 230 | $354,732 |
| EliquisApixaban | 215 | $294,511 |
| MounjaroTirzepatide | 69 | $112,039 |
| JardianceEmpagliflozin | 67 | $105,048 |
| TrulicityDulaglutide | 61 | $88,861 |
| Tresiba Flextouch U-200Insulin Degludec | 65 | $65,703 |
| MyrbetriqMirabegron | 52 | $58,162 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 36 | $56,704 |
| XareltoRivaroxaban | 37 | $56,120 |
| FarxigaDapagliflozin Propanediol | 46 | $50,986 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 25 | $32,832 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $25,074 |
| JanuviaSitagliptin Phosphate | 30 | $24,903 |
| RybelsusSemaglutide | 12 | $22,427 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 17 | $17,559 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $660 | $377,159242 claims |
| PfizerEliquis | $370 | $294,511215 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $355 | $206,279142 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $413 | $117,76682 claims |
| AstraZenecaFarxiga, Symbicort | $287 | $62,39569 claims |
| Astellas Pharma US IncMyrbetriq | $790 | $58,16252 claims |
| Johnson & JohnsonXarelto | $242 | $56,12037 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $410 | $37,00840 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $236 | $32,83225 claims |
| MerckJanuvia | $38 | $24,90330 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 928 family medicine providers in Utah.
Other family medicine in Draper
- Jessica WilkinsonDraper$185K
- Matthew AndersenDraper$130K
- John HemmersmeierOgden$24.9M
- Judith KirsteinWest Jordan$22.7M
- Matthew JohnstonSalt Lake City$20.9M
- Jared ProbstSalt Lake City$18.8M
- Bryce PetersonBountiful$16M
- Sarang YoonSalt Lake City$9.4M
- Michael AdamsSandy$8.1M
- Katie JulienSouth Jordan$7.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.